Therapeutic advances in pancreatic cancer.
暂无分享,去创建一个
M. Tempero | A. Lowy | H. T. Tran Cao | Margaret A Tempero | Andrew M Lowy | Hop S Tran Cao | Andrew Scott Paulson | A. Paulson
[1] M. Herrera,et al. [Laparoscopic surgery of pancreas]. , 2004, Revista de gastroenterologia de Mexico.
[2] R. Miksad,et al. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Chauffert,et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] E. Van Cutsem,et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Nakakura,et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] A. Chang,et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.
[7] Chang Moo Kang,et al. Is Robot-assisted Minimally Invasive Distal Pancreatectomy Superior to the Laparoscopic Technique? , 2015, Annals of surgery.
[8] J. Quivey,et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.
[9] J. Jeekel,et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.
[10] H. Friess,et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.
[11] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Makary,et al. Laparoscopic Distal Pancreatectomy Is Associated With Significantly Less Overall Morbidity Compared to the Open Technique: A Systematic Review and Meta-Analysis , 2012, Annals of surgery.
[13] M. Löhr,et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. , 2005, Neoplasia.
[14] K. Syrigos,et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.
[15] E. Touboul,et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Cameron,et al. Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study , 2010, Annals of Surgical Oncology.
[17] A. Cuschieri,et al. Laparoscopic surgery of the pancreas. , 1994, Journal of the Royal College of Surgeons of Edinburgh.
[18] A. Maitra,et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Ellenberg,et al. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.
[20] D. Gandara,et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer , 2012, Investigational New Drugs.
[21] N. Girard,et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Jeffrey E. Lee,et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Desai,et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis , 2007, Cancer Chemotherapy and Pharmacology.
[24] Amer H. Zureikat,et al. The current state of robotic-assisted pancreatic surgery , 2012, Nature Reviews Gastroenterology &Hepatology.
[25] K. Hess,et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.
[26] H. El‐Serag,et al. The epidemiology of pancreatic cancer in the United States: changes below the surface , 2006, Alimentary pharmacology & therapeutics.
[27] B. Erickson,et al. Phase II Study of External Irradiation and Weekly Paclitaxel for Nonmetastatic, Unresectable Pancreatic Cancer: RTOG-98-12 , 2004, American journal of clinical oncology.
[28] P. Senthilnathan,et al. Evolution in techniques of laparoscopic pancreaticoduodenectomy: a decade long experience from a tertiary center. , 2009, Journal of hepato-biliary-pancreatic surgery.
[29] Jeffrey E. Lee,et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Kendrick,et al. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. , 2010, Archives of surgery.
[31] W. Scheithauer,et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Schilsky,et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Jeffrey E. Lee,et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] G. Weiss,et al. Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer , 2011, Annals of Surgical Oncology.
[35] E. Chatzaki,et al. Molecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives , 2011, Oncology.
[36] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[37] Pietro Addeo,et al. Robot-assisted laparoscopic pancreatic surgery: single-surgeon experience , 2010, Surgical Endoscopy.
[38] Jeffrey E. Lee,et al. Post‐therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation , 2012, Cancer.
[39] E. Van Cutsem,et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.
[40] T. Conroy,et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] F. Ames,et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.
[42] Adam P Dicker,et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.
[43] R. Labianca,et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.
[44] P. Kienle,et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.
[45] Helen Hickey,et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.
[46] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[47] W. Scheithauer,et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. Moser,et al. Outcomes After Robot-Assisted Pancreaticoduodenectomy for Periampullary Lesions , 2012, Annals of Surgical Oncology.
[49] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[50] J. Cameron,et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. , 1991, American journal of surgery.
[51] A. Mahajna,et al. Laparoscopic pancreaticoduodenectomy for benign and malignant diseases , 2006, Surgical Endoscopy And Other Interventional Techniques.
[52] G. Klöppel,et al. Frequency of Kras Mutations in Pancreatic Intraductal Neoplasias Associated with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis : A Meta-Analysis 1 , 2014 .
[53] Jeffrey E. Lee,et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[55] Jeffrey E. Lee,et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.
[56] L. Fernández‐Cruz,et al. Curative Laparoscopic Resection for Pancreatic Neoplasms: A Critical Analysis from a Single Institution , 2007, Journal of Gastrointestinal Surgery.
[57] L. Diaz,et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.
[58] A. Ko. FOLFIRINOX: a small step or a great leap forward? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Daniel G Haller,et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] John R. Mackey,et al. The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.
[61] Jeffrey E. Lee,et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.
[62] R. Labianca,et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Alison P. Klein,et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] G. Maddern,et al. Evolution in technique of laparoscopic pancreaticoduodenectomy: a decade long experience from a tertiary center , 2009, Journal of hepato-biliary-pancreatic sciences.
[66] H. Einsele,et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] David Cella,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Peter Neuhaus,et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.
[69] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[70] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] A. Pomp,et al. Laparoscopic pylorus-preserving pancreatoduodenectomy , 1994, Surgical Endoscopy.
[72] Franco Mosca,et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.
[73] Douglas B. Evans,et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.
[74] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] D. Tait,et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy , 2007, British Journal of Cancer.
[77] Jeffrey E. Lee,et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.
[78] R. Abrams,et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] A. Khorana,et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] F. McCormick,et al. Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.
[81] J. Hainsworth,et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] K. Lillemoe,et al. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? , 2010, Journal of the American College of Surgeons.
[83] R. Abrams,et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.
[84] Kenneth J. Chang,et al. Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.
[85] Carlos Cuevas,et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[86] T. Ciuleanu,et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.